HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer

Yonesaka, K; Tanizak, J; Maenishi, O; Haratani, K; Kawakami, H; Tanaka, K; Hayashi, H; Sakai, K; Chiba, Y; Tsuya, A; Goto, H; Otsuka, E; Okida, H; Kobayashi, M; Yoshimoto, R; Funabashi, M; Hashimoto, Y; Hirotani, K; Kagari, T; Nishio, K; Nakagawa, K

Yonesaka, K (通讯作者)，Kindai Univ, Fac Med, Dept Med Oncol, 377-2 Ohno Higashi, Osaka, Osaka 5898511, Japan.

CLINICAL CANCER RESEARCH, 2022; 28 (2): 390

Abstract

Purpose: EGFR-tyrosine kinase inhibitor (TKI) is a standard first-line therapy for activated EGFR-mutated non-small cell lung cancer (NSCLC). Treatmen......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索